Testosterone therapy causes internal breast tissue changes, but it typically does not reduce breast size in a way most people would notice by looking in the mirror. The glandular tissue inside the breast gradually shrinks over months and years on testosterone, yet the fat that makes up much of breast volume tends to stay put. For most people, the visible cup size change is modest at best.
What Testosterone Actually Does to Breast Tissue
Breasts are made up of three main components: glandular tissue (the milk-producing lobules), fibrous connective tissue that provides structure, and fat. Testosterone primarily targets the glandular portion. In a study published in Breast Cancer Research, people on testosterone therapy had 28% less glandular tissue compared to those not taking testosterone. The longer someone used testosterone, the more pronounced this shrinkage became.
Fat content, however, stayed essentially unchanged. Since fat often accounts for a large share of total breast volume, especially in people with higher body weight, the internal glandular shrinkage doesn’t necessarily translate into a visible size difference. Think of it like removing some of the filling from a pillow while leaving the rest intact: the structure changes on the inside, but the outer shape may look similar.
How Quickly These Changes Happen
Glandular atrophy is a slow process. A study in Modern Pathology tracked over 400 individuals and found a clear relationship between time on testosterone and the degree of tissue change. At a median of about 8.5 months, most people showed only minimal shrinkage (25% or less of the glandular tissue affected). By around 16 months, moderate atrophy was typical, with roughly half to three-quarters of the glandular tissue reduced. Marked atrophy, where more than 75% of glandular tissue had shrunk, took a median of about 23 months.
Most people who had been on testosterone for at least 12 months showed moderate glandular atrophy. So while the tissue does respond, it takes well over a year to see the more significant internal changes, and even then the external appearance may not shift dramatically.
Why Visible Size Doesn’t Change Much
UCSF’s transgender health guidelines put it plainly: your chest will not change much in response to testosterone therapy. The reasons come down to anatomy. Testosterone redistributes body fat away from the hips, thighs, and buttocks and toward the abdomen, but the fat within the breast itself doesn’t reliably follow that pattern. Research confirmed that fat content in breast tissue showed no statistically significant decrease even after extended testosterone use.
Body weight plays a role too. People with a higher BMI tend to have more fatty breast tissue, which means testosterone-driven glandular changes make an even smaller dent in overall size. People who are leaner may notice a slightly more visible change simply because glandular tissue makes up a proportionally larger share of their breast volume.
Natural Testosterone Elevation and Breast Development
Conditions that cause naturally high testosterone levels in females, like polycystic ovary syndrome (PCOS) or congenital adrenal hyperplasia, offer some indirect evidence. Androgen excess from adrenal tumors or hyperplasia can suppress normal breast development in adolescent girls, even when estrogen levels appear adequate. This suggests that elevated testosterone during puberty can limit how much breast tissue grows in the first place. However, for adults whose breasts have already fully developed, having naturally higher testosterone levels does not cause the breasts to shrink back down.
Effects on Breast Density and Screening
One question researchers have been investigating is whether the internal tissue changes from testosterone show up on mammograms. So far, the answer is no. Despite the measurable reduction in glandular tissue, studies have found no significant change in mammographic breast density among testosterone users. The glandular and connective tissue decreases may simply not be large enough to alter what a radiologist sees on imaging.
There is some evidence that testosterone-related glandular atrophy could lower breast cancer risk, particularly in people with a normal BMI. This aligns with the observation that conditions causing long-term high testosterone, like PCOS, are not associated with increased breast cancer rates. But this area is still being studied, and current screening recommendations for people on testosterone generally haven’t changed based on these findings.
Why Most People Still Pursue Surgery
Because testosterone alone rarely produces a dramatic external change, the vast majority of transgender men and transmasculine individuals who want a flat chest pursue top surgery. Surgeons typically recommend waiting at least 6 to 12 months after starting testosterone before having the procedure. This waiting period allows the chest wall muscles and surrounding soft tissues to settle into their new contours under the influence of testosterone, which can improve surgical outcomes and help the surgeon plan the best approach.
The limited visible change from testosterone alone is one of the most commonly cited reasons for pursuing surgery. Even after years on hormone therapy, many people report little to no meaningful reduction in cup size. Binding remains a common interim approach for managing chest dysphoria while waiting for or deciding on surgical options.